- Revance Therapeutics (NASDAQ:RVNC -0.6%) expects operations to consume $117M - 137M in cash this year as it winds up clinical development of DaxibotulinumtoxinA for Injection (RT002) for the treatment of glabellar lines (frown lines). Assuming positive results from a long-term safety study, expected to be completed in H2, a U.S. marketing application should be filed in H1 2019.
- The company plans to launch a Phase 3 trial assessing RT002 in cervical dystonia, an Orphan Drug indication, in Q2.
- Preliminary results from a Phase 2a proof-of-concept study of RT002 in plantar fasciitis should be released within the next several weeks.
- Related ticker: AGN